Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance

Smycz‑Kubańska,Marta; Stępień,Sebastian; Gola,Joanna Magdalena; Kruszniewska‑Rajs,Celina; Wendlocha,Dominika; Królewska‑Daszczyńska,Patrycja; Strzelec,Anna; Strzelczyk,Jarosław; Szanecki,Wojciech; Witek,Andrzej; Mielczarek‑Palacz,Aleksandra

doi:10.3892/mmr.2022.12812

Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance

Authors:
- Marta Smycz‑Kubańska
- Sebastian Stępień
- Joanna Magdalena Gola
- Celina Kruszniewska‑Rajs
- Dominika Wendlocha
- Patrycja Królewska‑Daszczyńska
- Anna Strzelec
- Jarosław Strzelczyk
- Wojciech Szanecki
- Andrzej Witek
- Aleksandra Mielczarek‑Palacz
View Affiliations

Affiliations: Department of Immunology and Serology, Faculty of Pharmaceutical Sciences in Sosnowiec, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40‑055 Katowice, Poland, Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40‑055 Katowice, Poland, Department of Gynecology and Obstetrics, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 40‑055 Katowice, Poland
Published online on: August 2, 2022 https://doi.org/10.3892/mmr.2022.12812
Article Number: 296
Copyright: © Smycz‑Kubańska et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Understanding the relationship between the coexistence of inflammatory and neoplastic processes in ovarian cancer, particularly those involving chemokines and their receptors, may help to elucidate the involvement of the studied parameters in tumor pathogenesis and could lead to improved clinical applications. Therefore, the present study aimed to analyze the levels of C‑X‑C motif chemokine ligand 8 (CXCL8), and its receptors C‑X‑C chemokine receptor (CXCR)1 and CXCR2, in the serum and peritoneal fluid of women with ovarian cancer, and to evaluate the association between the expression of these parameters in tumor tissue and patient characteristics, particularly the degree of histological differentiation. The study group included women with ovarian cancer diagnosed with serous cystadenocarcinoma International Federation of Gynecology and Obstetrics stage IIIc and a control group, which consisted of women who were diagnosed with a benign lesion (serous cystadenoma). The transcript levels of CXCL8, CXCR1 and CXCR2 were evaluated using reverse transcription‑quantitative PCR (RT‑qPCR). The quantitative analysis was carried out using the LightCycler® 480 System and GoTaq® 1‑Step RT‑qPCR System, according to the manufacturers' instructions. The concentration of CXCL8 in serum and peritoneal fluid was determined using a Human Interleukin‑8 ELISA kit, and the concentrations of CXCR1 and CXCR2 were determined using the CLOUD‑CLONE ELISA kit. Local and systemic disturbances in immune and inflammatory responses involving the CXCL8 chemokine and its receptors indicated the involvement of these studied parameters in the pathogenesis of ovarian cancer. Immunoregulation of the CXCL8‑CXCR1 system may influence the course of the inflammatory process accompanying ovarian cancer development, which may result in the identification of novel clinical applications; however, further studies are required.

View Figures

View References

1	Jin Y, Lin Q, Fei H, Xue L, Li L, Xi Q and Jiang H: Bioinformatics analysis of potential therapeutic targets and prognostic biomarkers amid CXC chemokines in ovarian carcinoma microenvironment. J Oncol. 2021:88595542021. View Article : Google Scholar
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Keyvani V, Farshchian M, Esmaeili SA, Yari H, Moghbeli M, Nezhad SK and Abbaszadegan MR: Ovarian cancer stem cells and targeted therapy. J Ovarian Res. 12:1202019. View Article : Google Scholar : PubMed/NCBI
4	Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G and Jin WL: Immunotherapy for ovarian cancer: Adjuvant, combination, and neoadjuvant. Front Immunol. 11:5778692020. View Article : Google Scholar
5	Gaona-Luviano P, Medina-Gaona LA and Magaña-Pérez K: Epidemiology of ovarian cancer. Chin Clin Oncol. 9:472020. View Article : Google Scholar
6	Cortez AJ, Tudrej P, Kujawa KA and Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 81:17–38. 2018. View Article : Google Scholar
7	Bogani G, Lopez S, Mantiero M, Ducceschi M, Bosio S, Ruisi S, Sarpietro G, Guerrisi R, Brusadelli C, Dell'Acqua A, et al: Immunotherapy for platinum-resistant ovarian cancer. Gynecol Oncol. 158:484–488. 2020. View Article : Google Scholar
8	Arora T, Mullangi S and Lekkala MR: Ovarian cancer. StatPearls [Internet]. StatPearls Publishing; Treasure Island, FL: 2022
9	Zhang M, Cheng S, Jin Y, Zhao Y and Wang Y: Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 1875:1885032021. View Article : Google Scholar : PubMed/NCBI
10	Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN and Kampan NC: New predictive biomarkers for ovarian cancer. Diagnostics (Basel). 11:4652021. View Article : Google Scholar : PubMed/NCBI
11	Gonzalez-Aparicio M and Alfaro C: Significance of the IL-8 pathway for immunotherapy. Hum Vaccin Immunother. 16:2312–2317. 2020. View Article : Google Scholar : PubMed/NCBI
12	Marchewka Z, Gielniak M and Piwowar A: The role of selected mediators of inflammation in the pathogenesis of cancer. Postepy Hig Med Dosw. 72:175–183. 2018. View Article : Google Scholar
13	Łukaszewicz-Zając M, Pączek S, Mroczko P and Kulczyńska-Przybik A: The significance of CXCL1 and CXCL8 as Well as their specific receptors in colorectal cancer. Cancer Manag Res. 12:8435–8443. 2020. View Article : Google Scholar
14	Turnquist C, Ryan BM, Horikawa I, Harris BT and Harris CC: Storms in cancer and COVID-19. Cancer Cell. 38:598–601. 2020. View Article : Google Scholar
15	Kumar S, O'Malley J, Chaudhary AK, Inigo JR, Yadav N, Kumar R and Chandra D: Hsp60 and IL-8 axis promotes apoptosis resistance in cancer. Br J Cancer. 121:934–943. 2019. View Article : Google Scholar : PubMed/NCBI
16	Friedman A and Liao KL: The role of the cytokines IL-27 and IL-35 in cancer. Math Biosci Eng. 12:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
17	Groblewska M, Litman-Zawadzka A and Mroczko B: The role of selected chemokines and their receptors in the development of gliomas. Int J Mol Sci. 21:37042020. View Article : Google Scholar
18	Lane D, Matte I, Rancourt C and Piché A: Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 11:2102011. View Article : Google Scholar : PubMed/NCBI
19	Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T, Chen Y, Han X and Wu K: The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 31:61–71. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ha H, Debnath B and Neamati N: Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 7:1543–1588. 2017. View Article : Google Scholar : PubMed/NCBI
21	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
22	Antonosante A, Brandolini L, d'Angelo M, Benedetti E, Castelli V, Maestro MD, Luzzi S, Giordano A, Cimini A and Allegretti M: Autocrine CXCL8-dependent invasiveness triggers modulation of actin cytoskeletal network and cell dynamics. Aging (Albany NY). 12:1928–1951. 2020. View Article : Google Scholar : PubMed/NCBI
23	Gales D, Clark C, Manne U and Samuel T: The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol. 2013:8591542013.
24	Nolen BM and Lokshin AE: Biomarker testing for ovarian cancer: Clinical utility of multiplex assays. Mol Diagn Ther. 17:139–146. 2013. View Article : Google Scholar : PubMed/NCBI
25	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar
26	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
27	Jia D, Nagaoka Y, Katsumata M and Orsulic S: Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep. 8:123942018. View Article : Google Scholar : PubMed/NCBI
28	Savant SS, Sriramkumar S and O'Hagan HM: The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. Cancers (Basel). 10:2512018. View Article : Google Scholar
29	Wen J, Zhao Z, Huang L, Wang L, Miao Y and Wu J: IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer. J Cell Mol Med. 24:1588–1598. 2020. View Article : Google Scholar : PubMed/NCBI
30	Browne A, Sriraksa R, Guney T, Ramac N, Van Noordena S, Curryc E, Gabrac H, Stronachc E and El-Bahrawy M: Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine. 64:413–421. 2013. View Article : Google Scholar : PubMed/NCBI
31	Crispim PCA, Jammal MP, Antão PKA, Micheli DC, Tavares-Murta BM, Murta EFC and Nomelini RS: IL6, IL8, and IL10 in the distinction of malignant ovarian neoplasms and endometriomas. Am J Reprod Immunol. 84:e133092020. View Article : Google Scholar
32	Zhang L, Liu W, Wang X, Wang X and Sun H: Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy. Oncol Lett. 17:2365–2369. 2019.
33	Yang M, Zhang G, Wang Y, He M, Xu Q, Lu J, Liu H and Xu C: Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer. Br J Cancer. 123:1404–1416. 2020. View Article : Google Scholar : PubMed/NCBI
34	Thongchot S, Jamjuntra P, Therasakvichya S, Warnnissorn M, Ferraresi A, Thuwajit P, Isidoro C and Thuwajit C: Interleukin-8 released by cancer-associated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells. Int J Oncol. 58:142021. View Article : Google Scholar
35	Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, et al: Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 22:3924–3936. 2016. View Article : Google Scholar : PubMed/NCBI
36	Henriques TB, Dos Santos DZ, Dos Santos Guimarães I, Tessarollo NG, Lyra-Junior PCM, Mesquita P, Pádua D, Amaral AL, Cavadas B, Pereira L, et al: Inhibition of CXCR2 plays a pivotal role in re-sensitizing ovarian cancer to cisplatin treatment. Aging (Albany NY). 13:13405–13420. 2021. View Article : Google Scholar : PubMed/NCBI
37	Duckworth C, Zhang L, Carroll SL, Ethier SP and Cheung HW: Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression. Oncogene. 35:4036–4047. 2016. View Article : Google Scholar : PubMed/NCBI
38	Stronach EA, Cunnea P, Turner C, Guney T, Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB, et al: The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. Oncotarget. 6:31593–31603. 2015. View Article : Google Scholar
39	Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura E, et al: Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun. 9:16852018. View Article : Google Scholar : PubMed/NCBI
40	Han ZJ, Li YB, Yang LX, Cheng HJ, Liu X and Chen H: Roles of the CXCL8-CXCR1/2 axis in the tumor microenvironment and immunotherapy. Molecules. 27:1372021. View Article : Google Scholar : PubMed/NCBI
41	Liubomirski Y, Lerrer S, Meshel T, Rubinstein-Achiasaf L, Morein D, Wiemann S, Körner C and Ben-Baruch A: Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer. Front Immunol. 10:7572019. View Article : Google Scholar